We are live on ! Find out more
BOLD

Audentes Therapeutics, Inc
BOLD

Delisted

BOLD was delisted on the 14th of January, 2020.

Back to rankings

81 hedge funds and large institutions have $660M invested in Audentes Therapeutics, Inc in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 6

61% more capital invested

Capital invested by funds: $409M → $660M (+$251M)

16% more funds holding

Funds holding: 70 → 81 (+11)

4% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 23

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
81
Holders Change
+11
Holders Change %
+15.71%
% of All Funds
2.02%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
18
Increased
24
Reduced
23
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$64.1M
2
AG
Artal Group
Luxembourg
+$4.34M
3
AC
Ascend Capital
California
+$3.3M
4
Morgan Stanley
Morgan Stanley
New York
+$2.88M
5
Citadel Advisors
Citadel Advisors
Florida
+$2.19M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$14.6M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$6.13M
3
BlackRock
BlackRock
New York
-$5.06M
4
DM
Deerfield Management
New York
-$4.43M
5
RG
Redmile Group
California
-$3.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$3.4M -$1.3M -60,095 -33%
Citadel Advisors
27
Citadel Advisors
Florida
$3.11M +$2.19M +100,663 +981%
LCM
28
Laurion Capital Management
New York
$2.82M +$2.18M +100,600 New
SFM
29
Sphera Funds Management
Israel
$2.66M -$1.19M -55,000 -37%
JP Morgan Chase
30
JP Morgan Chase
New York
$2.29M -$148K -6,805 -8%
SIM
31
Spark Investment Management
New York
$2.25M +$1.74M +80,200 New
Victory Capital Management
32
Victory Capital Management
Texas
$1.99M -$40.2K -1,850 -3%
D.E. Shaw & Co
33
D.E. Shaw & Co
New York
$1.83M -$47.2K -2,174 -3%
HCM
34
Highbridge Capital Management
New York
$1.68M +$407K +18,720 +45%
TCIM
35
TIAA CREF Investment Management
New York
$1.63M -$139K -6,390 -10%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$1.53M +$39.6K +1,822 +3%
MCM
37
McKinley Capital Management
Alaska
$1.33M +$1.03M +47,594 New
Two Sigma Investments
38
Two Sigma Investments
New York
$956K +$741K +34,142 New
Bank of America
39
Bank of America
North Carolina
$882K +$64.6K +2,976 +10%
ECM
40
Endurant Capital Management
California
$819K +$760 +35 +0.1%
Russell Investments Group
41
Russell Investments Group
United Kingdom
$808K +$626K +28,840 New
TA
42
Teachers Advisors
New York
$754K – – –
Charles Schwab
43
Charles Schwab
California
$718K – – –
TD Asset Management
44
TD Asset Management
Ontario, Canada
$705K -$2.17K -100 -0.4%
AAP
45
Ardsley Advisory Partners
Connecticut
$702K +$109K +5,000 +25%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$692K -$49.6K -2,286 -8%
HCMT
47
Highland Capital Management (Texas)
Texas
$616K +$478K +22,000 New
PPA
48
Parametric Portfolio Associates
Washington
$595K -$328K -15,082 -42%
EIM
49
Essex Investment Management
Massachusetts
$490K +$380K +17,481 New
ProShare Advisors
50
ProShare Advisors
Maryland
$468K +$24.3K +1,117 +7%
1
2
3 4

BOLD Hedge Fund Activity: Q3 2017 in Review

81 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q3 2017, worth a combined $660M — up 61% from $409M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new BOLD positions and 6 closed out — a net gain of 12 holders — while 24 added to existing stakes and 23 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $64.1M. The largest seller was OrbiMed, cutting an estimated $14.6M.

  • 81 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q3 2017, up from 70 in Q2 2017.
  • Funds reported $660M of Audentes Therapeutics, Inc stock for Q3 2017, up 61% quarter-over-quarter.
  • 18 funds opened new Audentes Therapeutics, Inc positions in Q3 2017 and 6 closed out, a net change of +12 holders.
  • The largest Audentes Therapeutics, Inc buyer in Q3 2017 was Fidelity Investments, an estimated $64.1M added.
  • The largest Audentes Therapeutics, Inc seller in Q3 2017 was OrbiMed, an estimated $14.6M sold.

Based on aggregated 13F filings for Q3 2017.